Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease

Visit https://www.peervoice.com/RRA860 to view the entire programme with slides. After completing “Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease”, participants will be able to: Identify persistent gaps in the provision of patient-centred care for metastatic hormone-sensitive prostate cancer (mHSPC); Assess novel evidence related to PSA response and its association with clinical outcomes in patients with mHSPC; Evaluate the efficacy and safety of treatment regimens for mHSPC based on patient and disease characteristics such as age, disease volume, and disease risk; and Identify patient comorbidities, concomitant drug regimens, and preferences that may inform treatment planning in mHSPC.